Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027979 | 0.86 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1HPGDCYP3A4 | |
| SCHEMBL14228218 | 0.83 | ALDH1A1 (0.45) | MAPTMAPK1L3MBTL1ALDH1A1TSHR | |
| SCHEMBL69094 | 0.83 | TSHR (0.53) | MAPTMAPK1L3MBTL1ALDH1A1TSHR | |
| SCHEMBL4146537 | 0.81 | PNMT (0.53) | MAPTMAPK1L3MBTL1ALDH1A1TSHR | |
| SCHEMBL20476793 | 0.81 | IDO1 (0.41) | MAPTMAPK1L3MBTL1ALDH1A1TSHR | |
| SCHEMBL68857 | 0.81 | ALDH1A1 (0.43) | MAPTMAPK1L3MBTL1ALDH1A1TSHR | |
| SCHEMBL11090838 | 0.81 | HPGD (0.59) | MAPTMAPK1L3MBTL1ALDH1A1TSHR | |
| SCHEMBL670917 | 0.80 | TSHR (0.58) | MAPK1ALDH1A1TSHRTDP1GRIN2D | |
| SCHEMBL16310260 | 0.79 | TDP1 (0.45) | MAPTALDH1A1TSHRTDP1GRIN2D | |
| SCHEMBL1167739 | 0.79 | TSHR (0.53) | ALDH1A1TSHRTDP1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1865379-B1 | Method for resist pattern formation, and process for device prodution | CANON KK (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101086618-B | Photosensitive compound, photosensitive composition, method for resist pattern formation, and process for elements production | CANON KK | 2012-06-20 | — | — | CN | disclosed |
| US-8183234-B2 | Tricyclic guanidine derivatives as sodium-proton exchange inhibitors | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| US-8163730-B2 | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-04-24 | — | — | US | disclosed |
| US-8129087-B2 | Block copolymer and substrate processing method | CANON KABUSHIKI KAISHA (JP) | 2012-03-06 | — | — | US | disclosed |
| US-7964631-B2 | Fused tricyclic compounds as inhibitors of tumor necrosis factor-α | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100324026-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-12-23 | — | — | US | disclosed |
| US-20100305094-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-12-02 | — | — | US | disclosed |
| US-7834001-B2 | N-(10,10-Dioxo-10,11-dihydro-5-oxa-10-lambda*6*-thia-dibenzo[a.d]cycloheptene-8-carbonyl)-guanidine; tumor necrosis factor inhibitors; sodium-proton exchange inhibitors for treatment of organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-11-16 | — | — | US | disclosed |
| US-7834052-B2 | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-11-16 | — | — | US | disclosed |
| EP-1865379-A1 | Photosensitive compound, photosensitive composition, method for resist pattern formation, and process for device prodution | Canon Kabushiki Kaisha (JP) | 2007-12-12 | — | — | EP | disclosed |
| CN-101086618-A | Photosensitive compound, photosensitive composition, method for resist pattern formation, and process for elements production | CANON KK (JP) | 2007-12-12 | — | — | CN | disclosed |
| EP-1812420-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | Nicholas Piramal India Limited (IN) | 2007-08-01 | — | — | EP | disclosed |
| EP-1812419-A2 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | Nicholas Piramal India Limited (IN) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006051476-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006051477-A2 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2006-05-18 | — | — | WO | disclosed |
| US-6869960-B2 | N-substituted spiropiperidine compounds as ligands for ORL-1 receptor | PFIZER INC. (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1470126-A1 | N-SUBSTITUTED SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR | PFIZER INC. (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20030158219-A1 | N-substituted spiropiperidine compounds as ligands for ORL-1 receptor | ITO FUMITAKA (JP) | 2003-08-21 | — | — | US | disclosed |
| WO-2003064425-A1 | N-SUBSTITUTED SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR | PFIZER JAPAN INC. (JP) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324026-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | CD40, TNFRSF1A, OXER1 | MAPT 4579/4885MAPK1 3412/4885L3MBTL1 1993/4885 |
| US-20030158219-A1 | N-substituted spiropiperidine compounds as ligands for ORL-1 receptor | OGFRL1, OXER1, ORMDL3 | MAPT 4709/4885MAPK1 151/4885L3MBTL1 1797/4885 |
| US-20100305094-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | CD40, TNFRSF1A, OXER1 | MAPT 4666/4885MAPK1 3492/4885L3MBTL1 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.